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Abstract
Background
It has been suggested that the research priorities of those funding and performing research
in transplantation may differ from those of end service users such as patients, carers and
healthcare professionals involved in day-to-day care. The Kidney Transplant Priority Set-
ting Partnership (PSP) was established with the aim of involving all stakeholders in prioritis-
ing future research in the field.
Methods
The PSP methodology is as outlined by the James Lind Alliance. An initial survey collected
unanswered research questions from patients, carers and clinicians. Duplicate and out-of-
scope topics were excluded and the existing literature searched to identify topics answered
by current evidence. An interim prioritisation survey asked patients and professionals to
score the importance of the remaining questions to create a ranked long-list. These were
considered at a final consensus workshop using a modified nominal group technique to
agree a final top ten.
Results
The initial survey identified 497 questions from 183 respondents, covering all aspects of
transplantation from assessment through to long-term follow-up. These were grouped into
90 unanswered “indicative” questions. The interim prioritisation survey received 256
responses (34.8% patients/carers, 10.9% donors and 54.3% professionals), resulting in a
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ranked list of 25 questions that were considered during the final workshop. Participants
agreed a top ten priorities for future research that included optimisation of immunosuppres-
sion (improved monitoring, choice of regimen, personalisation), prevention of sensitisation
and transplanting the sensitised patient, management of antibody-mediated rejection, long-
term risks to live donors, methods of organ preservation, induction of tolerance and bioengi-
neering of organs. There was evidence that patient and carer involvement had a significant
impact on shaping the final priorities.
Conclusions
The final list of priorities relates to all stages of the transplant process, including access to
transplantation, living donation, organ preservation, post-transplant care and management
of the failing transplant. This list of priorities will provide an invaluable resource for
researchers and funders to direct future activity.
Introduction
Kidney transplantation is arguably the most successful treatment for end-stage kidney failure
in suitable patients, with evidence that demonstrates cost effectiveness, improved survival and
improved quality of life in comparison with patients remaining on dialysis [1,2]. Over 3,000
kidney transplants are performed each year in the United Kingdom, with 5-year graft survival
of around 85% [3].
Despite the success of kidney transplantation there are still challenges. The limited donor
pool means that access to transplantation is not universal, with a median waiting time of 1,022
days for adult patients in the United Kingdom resulting in a waiting list of around 5,600
patients at any one time [3]. Furthermore, despite successes in improving short-term graft sur-
vival, effective strategies to reduce longer-term graft loss have proved elusive [3,4].
Given these challenges, it is perhaps not surprising that the field of kidney transplantation
has a very active research community. The research agenda has typically been set by individual
researchers or industry, with over one third of randomised controlled trials in transplantation
receiving industry funding [5]. It has been suggested in other areas of health research that the
research priorities of these groups may differ from those of end service users such as patients,
carers and healthcare professionals involved in day-to-day care [6,7]. Whilst there are no pub-
lished studies examining the differences in research priorities between transplant patients and
professionals, two studies have reported differences between groups in patients with chronic
kidney disease (CKD), the scope of which included transplantation [8,9]. In particular, patients
tended to prioritise research into difficult to treat symptoms and side effects such as fatigue
and restless legs more highly than professionals.
Increasing recognition of a potential mismatch between the priorities of end service users
and researchers/funders has led to a drive towards involving healthcare professionals, patients
and carers in projects identifying and prioritising topics for research. This approach has been
championed by the James Lind Alliance in the UK, a not-for-profit organisation now a part of
the National Institute for Health Research (NIHR) Evaluation, Trials and Studies Coordinating
Centre (NETSCC). These “Priority Setting Partnerships” (PSPs) have been successful in a
number of areas of medicine, and have led to successful funding of many of the research ques-
tions identified [10–14].
UK Kidney Transplantation Priorities Setting Partnership
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The aims of the present study were (i) to identify unanswered research questions in the field
of kidney transplantation from end service users (patients, carers and healthcare professionals)
and (ii) to prioritise these questions according to the needs of these groups, for use in future
decisionmaking by funders and researchers.
Methods
The Kidney Transplant Priority Setting Partnership followed the methodologydescribed in
detail in the James Lind Alliance (JLA) guidebook [15]. In keeping with guidance from the
JLA, priority setting partnerships do not require specific ethical approval as they are considered
by the NHS Research Ethics Service (NRES) as service evaluation and development projects.
The ethical guidelines set out in the JLA guidebookwere followed throughout the process. Par-
ticipation in the surveys and workshop was entirely voluntary, and specific written consent (via
the online survey if used) for publication of research questions submitted/prioritisedwas
sought. Participants in the final workshop signed a declaration in advance to state that they
agreed with the principles of the project and to identify any potential conflicts of interest. The
methods used are included here in outline form. The PSP took place between January 2014 and
February 2016.
Organisation and scope
National patient and professional organisations and charities involved in kidney transplanta-
tion were contacted about the project and invited to contribute to a steering group. This group
included representation from the Centre for Evidence in Transplantation (CET), British Trans-
plantation Society (BTS), Renal Association (RA), British Renal Society (BRS), Kidney
Research UK (KRUK), the National Kidney Federation (NKF) and the British Kidney Patient
Association (BKPA). The group was chaired by an experienced advisor from the JLA (LM).
The steering group developed the protocol for the project and was involved in all stages of its
management. It included transplant surgeons, nephrologists, transplant recipients, living
donors and carers. Additional partner organisations were invited to take part in the process by
involving their members in the surveys and helping to promote the process. A full list of part-
ner organisations is included in the Supporting Information (S1 File).
The steering group also defined the scope of the project. This incorporated all stages of the
transplant process, including access to the waiting list and pre-transplant assessment, the trans-
plant procedure itself, post-transplant care in the short and long-term, management of the
failed transplant and issues surrounding retransplantation and living-donor transplantation.
Scope included both adult and paediatric patients and their carers and clinicians. In order to
maintain the focus of the process, it excludedmanagement of end-stage kidney failure other
than transplantation, donor selection and management (other than living donors) and issues
specific to combined organ transplants.
Identification of potential research questions
In order to identify potential research questions, an online surveywas created to collect possi-
ble questions, along with the demographic details of the respondents. The surveywas open-
ended, simply asking “What unanswered questions about kidney transplantation and living
donation would you like to see answered by research?” with space for up to three questions to
be submitted. The surveywas piloted by members of partner organisations and the wording
refined according to feedback. It was also made available in paper format to improve access.
The paper version included the same instructions and questions with the same wording as the
online version, and was made available on request. The surveywas open to responses between
UK Kidney Transplantation Priorities Setting Partnership
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October and December 2014, and promoted via the steering group, partner organisations and
other interested individuals.Methods of dissemination included websites, blogs, socialmedia,
society/organisation e-mailings and print newsletters distribution of flyers at conferences and
events and display of posters and leaflets in transplant centres. The surveywas open to all
transplant recipients and those on the transplant waiting list, their carers, live kidney donors
and professionals involved in the care of kidney transplant recipients in the UK. As the purpose
was to collect as many potential research questions as possible, multiple submissions from the
same respondent were allowed.
The steering group also identified two recent previous surveys from the BTS and KRUK to
which respondents were asked to submit potential research questions. Questions from these
surveys that fell within the scope of the PSP were also included, although demographic infor-
mation were not available.
Refinement of questions and identification of existing literature
The raw submissions were imported into a custom designedMySQL database. Responses were
reviewed by two researchers and those that were out of scope (as defined above), or that could
not be translated into an answerable research question, were identified. These questions were
reviewed by the entire steering group and only excluded if all members agreed.
The remaining questions were grouped into similar themes using a pre-defined taxonomy
to form a set of “indicative” research questions that covered the scope of all questions submit-
ted. These indicative questions were expressed in the PICO (population, intervention, compar-
ator, outcomes) format as far as possible, althoughmany questions were broad and all four
parameters were not defined. Classification and grouping was initially performed by two
researchers, with the results discussed in detail by the entire steering group to agree the final
indicative questions.
Two experienced systematic reviewers reviewed the transplant literature for each of the
remaining indicative uncertainties in order to assess the extent of the existing evidence. The
primary sources for this reviewwere the Cochrane Library and the Transplant Library (www.
transplantlibrary.com), which includes all randomised controlled trials and systematic reviews
(to a minimum quality standard) published in the field of solid organ transplantation between
1970 and present, identified from searches of MEDLINE the Cochrane Library and hand
searches of conference proceedings. The purpose of the literature reviewwas to identify any of
the questions that were considered adequately answered by the existing literature. In order for
a question to be considered answered, an existing up-to-date systematic reviewwith a clear
conclusion had to be identified.Questions with no available review, outdated reviews or with
an existing review that expressed uncertainty in its conclusions (due to lack of evidence, poor
quality evidence or imprecision in effect size) were considered unanswered. Questions consid-
ered answered were discussed in detail by the steering group prior to exclusion from the
remainder of the process. A full description of the strategy and search terms used to identify
existing reviews is provided in the Supporting Information (S2 File).
Interim prioritisation
In order to make a more manageable prioritisation survey (based upon previous JLA experi-
ence), remaining indicative questions submitted by three or more individuals to the initial sur-
vey were brought forward for prioritisation. A second online surveywas designed and piloted
in which respondents were asked to rate each remaining question on a five-point Likert scale
from “Not at all important” to “Extremely important”. Following an initial pilot, a glossary of
terms was also developed to help non-professional respondents understand some of the
UK Kidney Transplantation Priorities Setting Partnership
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medical terminology used in the questions. Demographic characteristics of respondents were
also collected, including age, sex, geographical region, ethnicity and role. The second survey
was open fromOctober to December 2015, and was promoted in a similar way to the initial
survey. All respondents to the initial surveywere contacted to participate in prioritisation,
although this surveywas also open to individuals who had not previously participated in the
process. Only one response per participant was allowed.
Responses to the prioritisation surveywere collated and the Likert scale coded numerically
from 1 (Not at all important) to 5 (Extremely important). The overall mean score as well as the
mean score for patients, donors and professionals were calculated for each question. Results
were reviewed by the steering group, and the decision was made to take the top 25 ranked ques-
tions overall through to the final workshop.
Final prioritisation workshop
A final one-day workshop was held in London in February 2016. The aim of the workshop was
to agree a top-ten list of prioritised questions for future research. Professionals (including
nephrologists, transplant surgeons and allied health professionals), patients and donors from
partner organisations were invited to attend and contribute via contact details submitted to the
two surveys, as well as organisation mailing lists, socialmedia and websites. Participants were
selectedwith the aim of broad representation of all involved groups and organisations. We ini-
tially planned to include around 25 participants in the final workshop, based upon optimal
numbers for interaction during previous JLA PSPs, as well as budget and space constraints.
Due to illness and unexpectedwork commitments, 20 individuals eventually participated.
The workshop took the form of a modifiednominal group process facilitated by experienced
JLA advisors. Participants were asked to rank the remaining 25 questions prior to attending the
workshop, and in an initial small group session these responses were discussed to identify any
agreement in the top and bottom three priorities. In a second small group session the groups
were asked to rank the uncertainties based upon this discussion. Groups were balanced to
ensure equal professional and non-professional involvement and the facilitators encouraged all
participants to take part and voice their opinions. Results of this ranking process from each
small group were fed back to the meeting as a whole, with agreement in the top and bottom
ranked questions highlighted. A further small group round (with different group composition)
took place to revise ranking based upon this feedback. In the final whole group session, the
results of the small group discussions were used to suggest a top-ten ranking, and discussion
took place as to whether items should be removed or inserted into the top ten. Where there
was disagreement, all participants were asked to vote in order to reach a decision. The results
of the interim prioritisation survey (including overall rankings and those from patients, donors
and professionals) were made available on request throughout the meeting to help inform
debate and decisionmaking. At the end of the meeting, a final top-ten questions were agreed as
priorities for future research.
Results
Identification of research questions
The initial survey received 440 potential research questions from 183 respondents. Responses
were from a mixture of professionals (36.1%), patients (37.7%), carers (2.2%) and live donors
(21.9%), although some donors also identified themselves as carers for a transplant recipient.
Full demographic details of respondents are described in Table 1. 57 further questions were
added from previous surveys from KRUK and the BTS, giving a total of 497 potential research
questions.
UK Kidney Transplantation Priorities Setting Partnership
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Submitted questions covered the breadth of kidney transplantation, and were categorised as
relating to recipient assessment, recipient education, access to the waiting list, organ allocation,
management of highly sensitised recipients, organ preservation and reconditioning, live donor
transplantation, non-directed donation, tissue typing and immunology, ABO and HLA incom-
patible transplantation, surgical technique and intra-operative management, post-transplant
complications, acute and chronic rejection, recurrent disease, psychosocial outcomes, diet and
lifestyle, management of the failing transplant, immunosuppression and tolerance, paediatric
and adolescent transplantation and organ bioengineering.
Refinement of questions and identification of existing literature
The flow of questions through the PSP process is outlined in Fig 1. Of the 497 submitted ques-
tions, 132 were out of scope or could not be framed as a research question. The remaining
Table 1. Demographics of respondents to the initial survey.
Characteristic N (%)
Role
Patient 69 (37.7)
Waiting list 10 (5.5)
Transplant recipient 59 (32.2)
Carer 4 (2.2)
Live donor 40 (21.9)
Healthcare professional 66 (36.1)
Nephrologist/physician 39 (21.3)
Transplant Surgeon 14 (7.7)
Nurse/co-ordinator 4 (2.2)
Clinical scientist 5 (2.7)
Other 4 (2.2)
Other 4 (2.2)
Age
Less than 18 years 0 (0)
18–24 years 3 (1.6)
25–34 years 17 (9.3)
35–44 years 39 (21.3)
45–54 year 50 (27.3)
55–64 years 38 (20.8)
65–74 years 27 (14.8)
75 or more years 4 (2.2)
Not specified 5 (2.7)
Sex
Male 91 (49.7)
Female 85 (46.4)
Not specified 7 (3.8)
Ethnicity
White 161 (88.0)
Mixed ethnicity 2 (1.1)
Asian/Asian British 12 (6.6)
Black/African/Caribbean/Black British 2 (1.1)
Not Specified 6 (3.3)
doi:10.1371/journal.pone.0162136.t001
UK Kidney Transplantation Priorities Setting Partnership
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submissions were collated into 97 indicative questions. Seven of these were considered by the
steering group to be adequately answered by existing research, and were excluded from the
remainder of the process. Of the remaining 90 questions, 45 were submitted by three or more
people and were taken forward for prioritisation (S3 File).
Interim prioritisation
The interim prioritisation survey received 256 responses from a mixture of patients (30.5%),
carers (4.3%), donors (10.9%) and professionals (54.3%). Full demographic details of those
responding are described in Table 2. Responses were analysed and the top 25 ranked questions
overall were taken through to the final workshop (Table 3).
There was evidence of a difference in priorities between patients, donors and professionals.
Of the 25 top-ranked questions, there was a difference in rankings of greater than 5 places
between patients and professionals for 16, between donors and professionals for 18 and
between patients and donors for 17. Whilst all groups prioritised questions regarding improv-
ing long-term transplant outcomes, patients tended to prioritise questions about immunosup-
pression (including side effects), organ preservation and equity of access. Professionals
prioritised questions about assessment of patient and organ suitability and management of
antibodymediated rejection.Donors prioritised questions regarding assessment of organ suit-
ability and promotion of living donation. The questions taken to the final workshop repre-
sented a mixture of those prioritised by all three groups.
Fig 1. Flow of submitted research questions through the prioritisation process.
doi:10.1371/journal.pone.0162136.g001
UK Kidney Transplantation Priorities Setting Partnership
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Final prioritization workshop
Twenty participants took part in the final workshop, representing patients (7), donors (4) and
professionals (9). During the day, it was decided that two of the questions had some degree of
overlap (regarding organ preservation and conditioning) and the group agreed to merge them
together. The top ten research priorities agreed are listed in Table 4. They cover all stages of the
transplant process, including optimisation of immunosuppression (improved monitoring,
choice of regimen, personalisation), prevention of sensitisation and transplanting the sensitised
patient, management of antibody-mediated rejection, long-term risks to live donors, methods
of organ preservation, induction of tolerance and bioengineeringof organs.
Of particular note was the desire of the participants in the final workshop to include realistic
questions achievable in the short term (for example those relating to the management of
immunosuppression) as well as questions that seemmuch further away from reality such as
Table 2. Demographics of respondents to the prioritisation survey.
Characteristic N (%)
Role
Patient 78 (30.5)
Waiting list 10 (3.9)
Transplant recipient 68 (26.6)
Carer 11 (4.3)
Live donor 28 (10.9)
Healthcare professional 139 (54.3)
Nephrologist/physician 71 (27.7)
Transplant Surgeon 26 (10.2)
Nurse/co-ordinator 21 (8.2)
Clinical scientist 11 (4.3)
Pharmacist 6 (2.3)
Other 4 (1.6)
Age
Less than 18 years 1 (0.4)
18–24 years 2 (0.8)
25–34 years 19 (7.4)
35–44 years 50 (19.5)
45–54 year 83 (32.4)
55–64 years 63 (24.6)
65–74 years 31 (12.1)
75 or more years 5 (2.0)
Not specified 2 (0.8)
Sex
Male 113 (44.1)
Female 130 (50.8)
Not specified 13 (5.1)
Ethnicity
White 222 (86.7)
Mixed ethnicity 4 (1.6)
Asian/Asian British 10 (3.9)
Black/African/Caribbean/Black British 1 (0.4)
Not Specified 19 (7.4)
doi:10.1371/journal.pone.0162136.t002
UK Kidney Transplantation Priorities Setting Partnership
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Table 3. The top 25 ranked questions from the prioritisation survey.
Question Rank
Overall Patients/
carers
Professionals Donors
Which treatments work best to prolong the life of the kidney transplant (for example different
immunosuppression, blood pressure control)?
1 1 1 2
Is there a reliable way for us to assess the suitability of individual organs for transplantation, and to
predict outcomes?
2 13 2 (=) 1
What is the best way to treat vascular or antibody mediated rejection? 3 8 2 (=) 12 (=)
How can we prevent sensitisation in patients with a failing transplant, to improve their chances of
another successful transplant? (e.g. removal of the transplant, withdrawal of immunosuppressive
medicines or continuation of these medicines?)
4 7 6 5
How can immunosuppression be personalised to the individual patient to improve the results of
transplantation?
5 4 (=) 5 15 (=)
What is the best combination of immunosuppressive drugs following kidney transplantation (for
example azathioprine or mycophenolate, belatacept, generic or proprietary (brand-name) drugs)?
6 2 11 12 (=)
How can we match organs to recipients to ensure the best overall outcomes (for example by age,
nephron dosing)?
7 4 (=) 7 6
What tests are required to determine whether a transplant is a suitable option for a patient? 8 6 8 20 (=)
For which patients is transplantation not suitable (considering factors such as age, body mass index,
history of cancer, co-morbidities)?
9 24 4 24 (=)
What is the best method of sharing deceased donor kidneys to ensure fair access to all age groups
whilst minimising waiting times?
10 11 (=) 17 7
How can we ensure fair and equal access to transplantation across the UK? 11 9 16 15 (=)
Can we improve monitoring of the level of immunosuppression to achieve better balance between risk
of rejection and side effects (for example T-cell or B-cell ELISPOT, point-of-care tacrolimus monitoring,
MMF monitoring)?
12 17 (=) 12 (=) 22
What techniques to preserve and transport the kidney before transplantation allow increased
preservation times and/or improve results (for example machine perfusion, normothermic
reconditioning)?
13 3 22 14
What are the long-term health risks to the living kidney donor? 14 22 12 (=) 19
What approaches improve outcomes in adolescent and young adult kidney transplant recipients? 15 17 (=) 14 30
Does routine screening for and treatment of donor-specific antibodies improve outcomes? What is the
most effective treatment?
16 25 9 28
How can we increase the number of potential living donors coming forward, and the proportion
proceeding to donation?
17 10 23 3
How can we improve transplant rates in highly-sensitised patients? 18 28 10 18
Which combinations of immunosuppressive drugs can minimise side effects in kidney transplant
recipients (such as infections, diarrhoea, malignancy)?
19 11 (=) 19 29
How can we encourage tolerance to the transplant to prevent or reduce the need for
immunosuppression (for example by use of T-regulatory cells, induction of haemoxygenase 1)?
20 20 20 10
For blood group incompatible transplants, which treatments most effectively reduce antibody levels
and improve the safety and outcomes of the operation?
21 21 21 26
Can bioengineered organs be developed to be as safe and effective as human-to-human transplants?
How can this be achieved?
22 16 25 9
Can adding substances to the storage or perfusion solution for the kidney improve preservation and
overall results (for example oxygenation, EPO, complement inhibitors, stem cells, scavenger
molecules)?
23 19 26 24 (=)
What is the best way of educating patients about transplantation before their operation? 24 15 28 20 (=)
How do we prevent the original cause of kidney failure returning (for example glomerulonephritis)
following kidney transplant?
25 26 29 4
Respondents were asked to score questions on a five-point Likert scale, and the mean score within each group (patients, professionals and donors) was
used to rank questions from highest to lowest score. (=) indicates questions ranked equally.
doi:10.1371/journal.pone.0162136.t003
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the development of bioengineeredorgans and induction of tolerance. The most highly priori-
tised question from the interim survey (“What is the best strategy to prolong the life of the
transplant kidney?”) was felt by the group to be too generic and covered by many of the more
specific questions under consideration, and so was not included in the final top ten.
Impact of non-professional involvement
A number of questions considered during the process were submitted by non-professionals,
and would not have been considered without their involvement. Of the 90 indicative questions
41 (45.5%) were submitted by professionals alone and 14 (15.6%) were submitted by non-pro-
fessionals alone; the remainder were submitted by both groups. Four questions submitted by
patients alone were taken through to the prioritisation stage. Of the final top ten questions, six
were originally submitted by both patients and professionals, and four by professionals alone.
The final top ten reflected the mixed priorities of all groups. Of the ten, five appeared in the
patient top ten during the prioritisation survey, four in the professional top ten, and two in the
donor top ten. Four of the final ten were rankedmore than five places higher by patients than
professionals, and four were rankedmore than five places higher by professionals.
Dissemination
The final list of priorities, as well as all research questions identified, have beenmade available
on the internet through both the PSP website (www.transplantpsp.org/kidney) and the JLA
website (http://www.jla.nihr.ac.uk). They were also disseminated to all partner organisations
and participants involved in the process, many of whom are involved in or fund transplant
research. The James Lind Alliance is part of the National Institute for Health Research (NIHR),
one of the largest funders of health research in the UK. The results of the Kidney Transplant
Table 4. Kidney Transplant PSP top ten priorities for future research.
Question
What is the best way to treat vascular or antibody-mediated acute rejection?
How can immunosuppression be personalised to the individual patients to improve the results of
transplantation?
How can we prevent sensitisation in patients with a failing transplant, to improve their chances of another
successful transplant (e.g. removal of the transplant, withdrawal of immunosuppressive medicines or
continuation of these medicines?)
Can we improve monitoring of the level of immunosuppression to achieve better balance between risk of
rejection and side effects? (e.g. T-cell or B-cell ELISPOT, point-of-care tacrolimus monitoring, MMF
monitoring)
How can we improve transplant rates in highly sensitised patients?
What are the long-term health risks to the living kidney donor?
How can we encourage tolerance to the transplant to prevent or reduce the need for immunosuppression?
(e.g. by use of T-regulatory cells, induction of haemoxygenase 1)
What is the best combination of immunosuppressive drugs following kidney transplantation? (e.g.
azathioprine or mycophenolate, belatacept, generic or proprietary (brand-name) drugs)
What techniques to preserve, condition and transport the kidney before transplantation allow increased
preservation times and/or improve results? (e.g. machine perfusion, normothermic reconditioning, addition
of agents to the perfusate)
Can bioengineered organs be developed to be as safe as human-to-human transplants? How can this be
achieved?
The order of questions does not reflect priority.
doi:10.1371/journal.pone.0162136.t004
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PSP have been discussedwith NIHR representatives in detail with the aim of taking forward
priorities for future specific funding calls.
Discussion
The Kidney Transplant PSP brought patients, donors and healthcare professionals together for
the first time in the United Kingdom to collect and prioritise topics for future research. The list
of research questions generated will be of interest to researchers and funders, and will hopefully
help to guide future themed calls to promote research in these areas. The list includes questions
relating to all stages of the transplant process, including access to transplantation, living dona-
tion and organ preservation, post-transplant care and management of the failing transplant. It
also includes questions relating to interventions which may be further on the horizon, but are
of such significance that their inclusion was deemed very important, such as the ability to bio-
engineer organs. Whilst the process has not necessarily identified any radical, previously
unconsidered questions, it has allowed us to assign shared priorities to these unanswered ques-
tions in order to help direct future research activity and funding.
The JLA process followed has now been used to identify research priorities in over 35 areas
of medicine (http://www.jla.nihr.ac.uk/), and the methodologyused fulfilsmany of the criteria
defined for good practice in priority setting [16,17]. The involvement of patients, carers and
donors at all stages including the planning and design of the project ensures that the views of
these groups are represented equally to those of healthcare professionals. Approximately equal
proportions of professionals and non-professionals engaged in each stage of this project.
Engagement of all major national professional and patient organisations and charities aided
the reach of the process, and will also help with dissemination of the final list of priorities to
ensure that they are addressed by future research.
The true impact of patient involvement in the PSP process is difficult as it was not formally
assessed.Most of the questions included in the final workshop and top ten were submitted by a
mixture of professionals or non-professionals, whilst questions submitted solely by patients
were uncommon. Nonetheless, some of the questions included in the final top ten were sug-
gested by far more patients than professionals (such as the long-term impacts of donor
nephrectomy). The final top ten included questions ranked highly by all groups during the
prioritisation process, with an equal mixture of those ranked highly by professionals and non-
professionals. It is likely, therefore, that patient involvement played an important role in the
shaping of the final prioritised list.
A recent systematic review identified four existing publications outlining research priorities
with a scope including kidney transplantation [18]. Of these, one focused solely on paediatric
transplantation [19], with the remainder considering all aspects of Chronic Kidney Disease
(CKD) [8,20,21]. Only one of these studies involved patients and professionals in partnership,
aiming to set research priorities for patients on or nearing dialysis [8]. Due to the patient popu-
lation and scope, the only question relating to transplantation reaching the top ten related to
improving access to transplantation. A more recent study has involved both patients and pro-
fessionals in prioritising research topics for CKD patients, considering transplantation as a
standalone category [9]. Potential questions were submitted by participants during a one-day
workshop, with 20 questions regarding transplantation considered. Of note, there were only 9
transplant recipients included in the group of 60 participants. In contrast, the current PSP pro-
cess involved over 250 participants, and considered 90 potential indicative research questions.
Whilst the many of the questions considered in this previous study were also identified in the
current process, the prioritisation was very different with a much greater focus on psychologi-
cal health and wellbeing of donors and recipients, as well as aspects of paediatric
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transplantation and organ donation. This likely reflects the differences in scope, the size of the
pool of questions considered, and differences in the composition and interests of the consensus
groups. It is however possible that differences in healthcare settings and/or cultural differences
between countries could impact the priorities identified.
The current process may under-represent certain groups affected by transplantation. In par-
ticular, very few responses were received from children and adolescents despite partnership
with children’s renal charities and the British Association for Paediatric Nephrology. However,
many respondents were parents of affected children or nephrologists involved in the treatment
of these patients, and questions regarding child and adolescent transplantation were considered
during the final workshop. The other patients under-represented in the current process are
those from black, Asian and minority ethnic (BAME) groups. These groups made up around
9% of the responses to the initial survey, and 5% of those to the prioritization survey, yet repre-
sent around one quarter of the patients on the UK transplant waiting list. BAME patients have
significantly higher waiting times to transplantation in the UK, and are less likely to donate [3].
Questions regarding access to transplantation in these groups were submitted to the PSP, and
the indicative question “In potential kidney transplant recipients, how can we ensure fair and
equal access to transplantation across the UK?” was considered in the top 25 questions during
the final workshop.
A further limitation of the current process is the relatively small number of participants in
the final workshop. A group size of around 25 participants was determined to provide optimal
interaction based upon experience from previous JLA PSPs, and within the budget limitations
of the project. Unfortunately, due to illness and unforeseen work commitments the final num-
ber of participants was reduced to 20. Despite this, the final group had fair and balanced repre-
sentation from all stakeholder groups including patients, donors and clinicians. Furthermore,
discussions during the final workshop were informed by the rankings of all groups during the
prioritisation survey, meaning that the final decisionmaking was influenced by a broader
group than just those involved in the workshop.
Whilst the prioritised results of this PSP are most relevant to the UK healthcare setting, it is
likely that the long-list of potential research questions has international relevance. The review
process to check whether questions were truly unanswered by existing literature included evi-
dence from all international healthcare settings, and so whilst it is conceivable that priorities
may differ, the unanswered questions are likely to remain the same. This notion is supported
by comparison of questions submitted to the current process and those submitted to previous
prioritisation processes in other healthcare settings, with significant overlap seen despite differ-
ences in priority [9]. One caveat to this is that both the current and other existing prioritisation
exercises were undertaken in high-income countries with well-developed and funded health-
care systems. Research priorities in developing countries may differ from those identified here.
Priority setting should not be seen as a one-time exercise, and the priorities set in this pro-
cess will require future re-evaluation to ensure continuing relevant or to identify new areas of
important uncertainty [16]. As yet, the JLA do not have a defined process for the re-evaluation
of research priorities, and this will becomemore important as time passes and more healthcare
areas are evaluated. The other area of paucity in the literature is the formal assessment of the
impact of such priority setting exercises on the research performed, and in particular the
impact of patient involvement [22]. Future evaluation of the questions addressed by success-
fully funded projects in the field will be essential to assess the impact of this project, although
measureable impact is likely to take a number of years.
The Kidney Transplant PSP has provided an invaluable resource of prioritized, unanswered
research questions to help in the design of future research studies. By increasing awareness of
these topics, we hope to divert research effort and funding towards the design and
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implementation of high quality studies, including collaborative randomised controlled trials,
with the goal of improving access to transplantation and the long-term outcomes for both
donors and recipients.
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